COAG (Hemab Therapeutics Holdings) PB Ratio: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
11 GF Score
Price $47.66
! 2 Warning Signs
View Full Analysis

What is Hemab Therapeutics Holdings PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-04), Hemab Therapeutics Holdings's share price is $47.6603. Hemab Therapeutics Holdings's Book Value per Share for the quarter that ended in Dec. 2025 was $-4.00. Hence, Hemab Therapeutics Holdings's PB Ratio of today is .

The historical rank and industry rank for Hemab Therapeutics Holdings's PB Ratio or its related term are showing as below:

COAG's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.765
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio

Hemab Therapeutics Holdings  (NAS:COAG) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.

Hemab Therapeutics Holdings PB Ratio Related Terms

Hemab Therapeutics Holdings PB Ratio Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings PB Ratio Chart

Hemab Therapeutics Holdings Annual Data
Trend Dec24 Dec25
PB Ratio
0.00 0.00

Hemab Therapeutics Holdings Semi-Annual Data
Dec24 Dec25
PB Ratio 0.00 0.00

COAG vs ZLAB, SLS, IOVA: PB Ratio Comparison

For the Biotechnology subindustry, Hemab Therapeutics Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemab Therapeutics Holdings PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemab Therapeutics Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Hemab Therapeutics Holdings's PB Ratio falls into.


COAG
11GF Score
Hemab Therapeutics Holdings Inc COAG
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Hemab Therapeutics Holdings's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=47.6603/-3.997
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PB Ratio=Market Cap /(Total Stockholders Equity-Preferred Stock)

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score

Get the complete analysis for COAG

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.66
Price